How Will the Market React to OpGen Inc (OPGN) Stock Getting a Bearish Rating

Overall market sentiment has been down on OpGen Inc (OPGN) stock lately. OPGN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

OpGen Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on OPGN!

See Full OPGN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With OPGN Stock Today?

OpGen Inc (OPGN) stock has fallen -6.31% while the S&P 500 has risen 0.7% as of 9:35 AM on Monday, Oct 16. OPGN is lower by -$0.05 from the previous closing price of $0.82 on volume of 270,201 shares. Over the past year the S&P 500 is higher by 18.49% while OPGN is lower by -80.70%. OPGN lost -$11.97 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for OpGen Inc click here.

More About OpGen Inc

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base. Click Here to get the full Stock Report for OpGen Inc stock.